Peter Shields

Peter Shields, MD


Make an Appointment




I’m a medical oncologist who specializes in the treatment of lung cancer. My research focus is on cancer prevention and the causes of cancer, with a focus on developing tests to identify people who are at the most risk of cancer. Although most of my research is about breast and lung cancer, with a heavy emphasis on tobacco products, it is not limited to that. My funding for the research comes from the federal government, foundations and the OSU Comprehensive Cancer Center. Importantly, I publish our research results regularly, with many articles appearing in respected journals almost monthly.

I currently direct several large research projects, including epidemiology studies and clinical trials funded by the National Cancer Institute. In the past, I directed a multi-institution contract from the National Cancer Institute toward developing new methods to study tobacco products. I also led a Department of Defense Breast Cancer Center of Excellence to understand why alcohol drinking causes breast cancer and is used as a paradigm for cancer risk relating to nutrition.

I’m a tenured professor in the department of internal medicine at The Ohio State University College of Medicine and in the division of epidemiology at the Ohio State University College of Public Health. I was named to the Castle Connolly list of “America's Top Doctors” from 2008-2019. Additionally, I have served as the president of the American Society of Preventive Oncology and am a fellow in the American College of Epidemiology. I’ve published more than 210 studies, with topics ranging from toxicology and epidemiology to behavior and health disparities.

One of my primary roles is deputy director of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). I oversee the scientific research programs and research infrastructure of OSUCCC – James that includes more than 270 cancer researchers from 11 of Ohio State’s 15 colleges.

This type of research happens only in a place that has researchers from a broad spectrum of disciplines working together to eradicate cancer. Ohio State is such a place – the breadth and depth of the researchers, as well as the infrastructure, is exceptional. It’s a privilege to be part of this collective effort.

Education and Background


Mount Sinai School of Medicine SUNY

New York, NY


George Washington University Medical Center

Washington, DC



George Washington University Medical Center

Washington, DC

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Shields has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

Burns White LLC

Forman Perry Watkins Krutz & Tardy

Norfolk Southern Corp.

Santa Fe Railroad

Schiff Hardin LLP

Steptoe & Johnson, LLP

Capes Sokol Law Firm

Duane Morris LLP

Boyle Brasher LLC


Hall Evans Law Firm

Harris Beach Law Firm

Humphrey, Farrington & McClain, P.C.

Kramon Law Firm

Milllberg Gordon LLC


Electronic vs Combustible Cigarette Effects on Inflammasome Component Release into Human Lung.

Tsai M, Song MA, McAndrew C, Brasky TM, Freudenheim JL, Mathé E, McElroy J, Reisinger SA, Shields PG, Wewers MD

Am J Respir Crit Care Med in press


Active and secondhand smoke exposure throughout life and DNA methylation in breast tumors.

Callahan CL, Bonner MR, Nie J, Wang Y, Tao MH, Shields PG, Marian C, Eng KH, Trevisan M, Freudenheim JL

Cancer Causes Control 30


Clinical Trials | Lead




Related Videos

New Initiative Aims to Improve Late-Stage Lung Cancer Care
Rise in Lung Adenocarcinoma Linked to Light Cigarette Use
So-Called ‘Light’ Cigarettes Likely Responsible for Rise in Some Lung Cancers
Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type